Affibody molecules as engineered protein drugs
Fredrik Y. Frejd,Kyu-Tae Kim +1 more
TL;DR: Early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man, and AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.
read more
Abstract: Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications
Ali W. Al-Ani,Francesco Zamberlan,Lenny Ferreira,Tracey D. Bradshaw,Neil R. Thomas,Lyudmila Turyanska +5 more
- 27 Oct 2021
TL;DR: In this article, a new theranostic device based on lead sulfide quantum dots (PbS QDs) with optical emission in the near infrared wavelength range decorated with affibodies (small 6.5 kDa protein-based antibody replacements) specific to the cancer biomarker human epidermal growth factor receptor 2 (HER2), and zinc(II) protoporphyrin IX (ZnPP) to combine imaging, targeting and therapy within one nanostructure.
Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer.
Haruka Yamaguchi,Jotaro On,Takao Morita,Takamasa Suzuki,Yasuo Okada,Junya Ono,Andreas Evdokiou +6 more
TL;DR: In this article, a combination of NIR-PIT with a small protein mimetic, the Affibody molecule (6-7 kDa), instead of a monoclonal antibody was investigated for HER2-positive breast cancer cells.
Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds.
Charlotte U. Zajc,Benjamin Salzer,Joseph M. Taft,Sai T. Reddy,Manfred Lehner,Michael W. Traxlmayr +5 more
TL;DR: It is critically discussed the risk of immunogenicity and shown that the extent of nonhuman amino acid stretches in engineered scaffolds—even in those based on nonhuman proteins—is more similar to humanized scFvs than might be anticipated.
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond
Javad Garousi,Anna Orlova,Anna Orlova,Anna Orlova,Fredrik Y. Frejd,Vladimir Tolmachev,Vladimir Tolmachev +6 more
TL;DR: An overview of biodistribution and tumour-seeking features of major classes of targeting proteins currently utilized for molecular imaging is provided to help researchers entering the field of the protein-based radionuclide molecular imaging.
Rapid, site-specific labeling of “off-the-shelf” and native serum autoantibodies with T cell–redirecting domains
Fabiana Zappala,Elizabeth Higbee-Dempsey,Bian Jang,Joann Miller,Lesan Yan,Nicholas G. Minutolo,Gabriela T Rosado González,Andrew Tsourkas,Burcin Altun Ozdemir +8 more
TL;DR: A simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum is developed, indicating a previously unexplored therapeutic window.
References
Untangling the ErbB signalling network
Yosef Yarden,Mark X. Sliwkowski +1 more
TL;DR: When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny,Ping Chiao,Thierry Bussiere,Paul H. Weinreb,Leslie Williams,Marcel Maier,Robert Dunstan,Stephen Salloway,Tianle Chen,Yan Ling,John O'Gorman,Fang Qian,Mahin Arastu,Mingwei Li,Sowmya Chollate,Melanie S. Brennan,Omar Quintero-Monzon,Robert H. Scannevin,H. Moore Arnold,Thomas Engber,Kenneth J. Rhodes,James Ferrero,Yaming Hang,Alvydas Mikulskis,Jan Grimm,Christoph Hock,Roger M. Nitsch,Alfred Sandrock +27 more
TL;DR: In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.
2.6K
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker,Christopher J. O'Callaghan,Christos S. Karapetis,John Zalcberg,Dongsheng Tu,Heather-Jane Au,Scott R. Berry,Marianne Krahn,Timothy J. Price,R. John Simes,Niall C. Tebbutt,Guy van Hazel,Rafal Wierzbicki,Christiane Langer,Malcolm J. Moore +14 more
TL;DR: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed.
•Journal Article
Cetuximab in the treatment of colorectal cancer.
1.7K
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gérard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe O. Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh Lin Fu,Jaroslaw P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto +19 more
TL;DR: Eculizumab is an effective therapy for PNH and Clinically significant improvements were found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
1.2K